Get the Stockscreener App
55.39
4.32%
-2.50
Pre-market:
55.08
-0.31
-0.56%
Mbx Biosciences Inc stock is traded at $55.39, with a volume of 638.96K.
It is down -4.32% in the last 24 hours and down -16.57% over the past month.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
See More
Previous Close:
$57.89
Open:
$57.56
24h Volume:
638.96K
Relative Volume:
1.00
Market Cap:
$2.67B
Revenue:
-
Net Income/Loss:
$-86.97M
P/E Ratio:
-22.90
EPS:
-2.4189
Net Cash Flow:
$-81.88M
1W Performance:
-13.30%
1M Performance:
-16.57%
6M Performance:
+99.10%
1Y Performance:
+175.57%
1-Day Range:
$54.41
$57.72
1-Week Range:
$54.41
$64.61
52-Week Range:
$12.94
$72.64
Mbx Biosciences Inc Stock (MBX) Company Profile
Name
Mbx Biosciences Inc
Sector
Industry
Phone
(317) 989-3100
Address
11711 N. MERIDIAN STREET, CARMEL
Compare MBX vs VRTX, REGN, MRNA, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MBX
Mbx Biosciences Inc
|
55.39 | 2.67B | 0 | -86.97M | -81.88M | -2.4189 |
VRTX
Vertex Pharmaceuticals Inc
|
522.38 | 132.40B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
796.02 | 81.95B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
194.82 | 77.78B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
962.22 | 60.20B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
199.86 | 42.84B | 742.00K | -1.37B | -1.07B | -7.0731 |
Mbx Biosciences Inc Stock (MBX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Dec-04-25 | Initiated | Goldman | Sell |
| Nov-04-25 | Initiated | TD Cowen | Buy |
| Oct-15-25 | Initiated | Truist | Buy |
| Aug-15-25 | Resumed | Jefferies | Buy |
| Aug-05-25 | Initiated | Mizuho | Outperform |
| Jul-16-25 | Initiated | Oppenheimer | Outperform |
| Apr-10-25 | Initiated | Citizens JMP | Mkt Outperform |
| Oct-08-24 | Initiated | Guggenheim | Buy |
| Oct-08-24 | Initiated | JP Morgan | Overweight |
| Oct-08-24 | Initiated | Jefferies | Buy |
| Oct-08-24 | Initiated | Stifel | Buy |
View All
Mbx Biosciences Inc Stock (MBX) Latest News
MBX Biosciences upgraded to Buy on strong Phase 2 data and promising Phase 3 outlook for hypoparathyroidism drug. - Pluang
MBX Biosciences: I Should Never Have Downgraded To Hold (Rating Upgrade) (NASDAQ:MBX) - Seeking Alpha
MBX BIOSCIENCES ANNOUNCES APPOINTMENT OF JEFF HELD AS CHIEF LEGAL OFFICER - Moomoo
MBX Biosciences, Inc. (NASDAQ:MBX) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
MBX Biosciences at Morgan Stanley conference: pipeline nears key tests By Investing.com - Investing.com Canada
MBXMBX Biosciences Inc Revenue Breakdown - Finviz
MBX Biosciences, Inc. (MBX) stock price, news, quote and history - Yahoo Finance Singapore
MBX Biosciences to Participate in Upcoming Investor Conferences - marketscreener.com
MBX Biosciences will present in New York and online - Stock Titan
MBX Biosciences, Inc. Announces Appointment of Jeff Held as Chief Legal Officer - marketscreener.com
MBX Biosciences Announces Appointment of Jeff Held as Chief Legal Officer - The Manila Times
MBX Biosciences Share Price Chart (MBX) - Investing.com UK
MBX Biosciences (MBX) Is Down 7.5% After Starting Phase 3 oPTimize Trial – Has The Bull Case Changed? - simplywall.st
MBX Q2 2026 Earnings: Wider-than-Expected Loss Pressures SharesEarnings Stability Report - vinanet.vn
MBX Biosciences (MBX), Why Is It Getting So Much Attention Now? - sahmcapital.com
MBX Biosciences doses first patient in phase 3 HP trial - Investing.com
MBX Biosciences (MBX) Slips 2.7% to $66.76, Holding Above Key Support at $63.42Price Target - careplusvn.com
MBX Biosciences Insiders Added US$1.06m Of Stock To Their Holdings - moomoo.com
MBX BIOSCIENCES, INC. : JP MORGAN RESUMES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $88 - Bitget
JPMorgan Chase & Co. Initiates Coverage on MBX Biosciences (NASDAQ:MBX) - MarketBeat
J.P. Morgan Maintains MBX Biosciences(MBX.US) With Buy Rating, Announces Target Price $88 - moomoo.com
Deep Track Capital Reduces MBX Biosciences Stake in Strategic Pr - GuruFocus
MBX (MBX) Move: Finishes 2.76% Lower at $66.51 on the Day; Technical View: the Supplied Trading Band Runs From $63.18 to $69.84 on the DayMean Reversion Trade - vinanet.vn
MBX (MBX) Snapshot: Finishes 0.13% Lower at $66.44 on the Day; Boundary Watch: $63.12 and $69.76 Define the Nearby Reference Levels for the Current SessionBollinger Squeeze - vinanet.vn
MBX Biosciences Q2 2026 Earnings: EPS of -$0.78 Misses Estimates as Clinical Costs MountRevenue Guidance Update - dars.gov.et
MBX Biosciences (NASDAQ: MBX) insider to sell 3,745 shares - Stock Titan
MBX Biosciences (MBX) Edges Lower to $68.12, Consolidating Between Support and ResistanceZigzag Correction - vinanet.vn
MBX Q2 2026 Earnings: Wider-than-Expected -$0.78 Loss Highlights Accelerated Pipeline InvestmentRevenue Estimate Trend - vinanet.vn
MBX Biosciences Inc (MBX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
California State Teachers Retirement System Purchases 21,011 Shares of MBX Biosciences, Inc. $MBX - MarketBeat
Deep Track Capital reports 3.64% MBX Biosciences (MBX) stake in 13G/A - Stock Titan
Stifel Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $70 - Moomoo
MBX Biosciences (MBX) Short Interest & Short Float | Updated Aug 2026 - MarketBeat
Frazier funds detail 10.8% MBX Biosciences stake (MBX) in ownership update - Stock Titan
OrbiMed trims MBX Biosciences (MBX) position to 6.4% after share sales - Stock Titan
Truist Adjusts Price Target on MBX Biosciences to $88 From $70, Maintains Buy Rating - Moomoo
MBX Biosciences, Inc. $MBX Stock Holdings Raised by The Manufacturers Life Insurance Company - MarketBeat
LifeSci Capital Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $121 - moomoo.com
MBX Biosciences (NASDAQ:MBX) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Mizuho Securities Maintains MBX Biosciences(MBX.US) With Buy Rating, Maintains Target Price $91 - Moomoo
MBX SWOT Analysis: Financial Challenges and Growth Potential Rev - GuruFocus
Barclays Maintains MBX Biosciences(MBX.US) With Buy Rating, Raises Target Price to $88 - Moomoo
MBX Biosciences (MBX) Stock Analysis: Strong Buy Ratings and Significant Upside Potential - DirectorsTalk Interviews
MBX Biosciences, Inc. Stock 12‑Month Price Target Raised to $84.8, Implies 26% Upside - TradingView
MBX Biosciences Shares Lower After Q2 Loss Widens - marketscreener.com
MBX Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
MBX Biosciences, Inc. reports results for the quarter ended June 30Earnings Summary - tradingview.com
Earnings Flash (MBX) MBX Biosciences Posts Q2 Net Loss $0.78 a Share, vs. FactSet Est of $0.63 Loss - marketscreener.com
MBX Biosciences posts Q2 loss, advances obesity pipeline By Investing.com - Investing.com Australia
MBX Biosciences posts Q2 loss, advances obesity pipeline - Investing.com
MBX Biosciences Reports Second Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
Mbx Biosciences Inc Stock (MBX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
1.87%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):